ON 104
Alternative Names: ON-104Latest Information Update: 28 Jun 2024
At a glance
- Originator OncoOne
- Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Macrophage migration-inhibitory factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Asthma; Inflammatory bowel diseases; Nephritis; Rheumatoid arthritis
Most Recent Events
- 26 Jun 2024 Preclinical trials in Nephritis in Austria (Parenteral) prior to June 2024 (OncoOne pipeline, June 2024)
- 12 Jun 2024 Updated pharmacodynamics and pharmacokinetics results from a preclinical trial in Rheumatoid arthritis was presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 30 Sep 2022 ON 104 is available for licensing as of 26 Sep 2022. https://www.oncoone.com/partner/